Final results of EFC6663: A multicenter, international, phase 2 study of alvocidib for patients with fludarabine-refractory chronic lymphocytic leukemia. Issue 5 (May 2015)

• Record Type: Journal Article
• Authors: Lanasa, Mark C.; Andritsos, Leslie; Brown, Jennifer R.; Gabrilove, Janice; Caligaris-Cappio, Federico; Ghia, Paolo; Larson, Richard A.; Kipps, Thomas J.; Leblond, Veronique; Milligan, Donald W.; Janssens, Ann; Johnson, Amy J.; Heerema, Nyla A.; Bühler, Andreas; Stilgenbauer, Stephan; Devin, Jeanne; Hallek, Michael; Byrd, John C.; Grever, Michael R.
• Is Part Of: Leukemia research. Volume 39:Issue 5(2015:May)
• Page Start: 495
• Page End: 500
• Publication Date: 2015-05
• Subjects: Leukemia -- Periodicals; Leukemia -- Periodicals; Leucémie -- Périodiques; Leukemia; Periodicals; Electronic journals; Electronic journals; 616.9941905
• DOI: 10.1016/j.leukres.2015.02.001
• Languages: English
• ISSNs: 0145-2126

Abstract

<abstract abstract-type="author-highlights" id="abs0005"> <title id="sect0005">Highlights</title> <sec> <p id="spar0005"> <list id="lis0005"> <list-item id="lsti0005"> <label></label> <p id="par0005">Flavopiridol has clinical activity in fludarabine-refractory CLL.</p> </list-item> <list-item id="lsti0010"> <label></label> <p id="par0010">Flavopiridol can promote durable remissions in a subset of high risk genomic CLL.</p> </list-item> <list-item id="lsti0015"> <label></label> <p id="par0015">Flavopiridol has a narrow therapeutic window requiring close monitoring.</p> </list-item> <list-item id="lsti0020"> <label></label> <p id="par0020">Unique to flavopiridol is hyperacute tumor lysis syndrome which can be life threatening.</p> </list-item> <list-item id="lsti0025"> <label></label> <p id="par0025">Future efforts with flavopiridol should focus on combination strategies.</p> </list-item> </list> </p> </sec> </abstract>